Amarillo Biosciences will begin a Phase II clinical trial of low-dose oral interferon alpha (IFNa) in the treatment of fibromyalgia (FM). The company said previous studies indicated that IFNa reduces pain and stiffness in some FM patients. Treatment with amitriptyline and either IFNa or placebo will last four months. Researchers are seeking 120 patients for the study, which will take place at the University of Texas Health Science Center in San Antonio under the direction of Dr. I. Jon Russell. Patient enrollment will be open until July 1999. Final results could be available in the first quarter of 2000. For information, write to Dr. Russell at: University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78284.
Investigators at Johns Hopkins Hospital and the National Institutes of Health continue to recruit CFS patients for a trial of fludrocortisone (Florinef) in those with CFS and neurally mediated hypotension (NMH). Participants must be 18–50 and free of other significant medical and psychiatric illnesses. The study has a target of 100 patients. There is no cost to the patient. For more information, call Karen DeBusk, RN, at Johns Hopkins at 800/624-4562.